Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Overview

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently recognized autoimmune demyelinating disorder characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a protein expressed on the surface of oligodendrocytes and myelin sheaths in the central nervous system [1](https://pubmed.ncbi.nlm.nih.gov/34912345/). Once considered a variant of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), MOGAD is now understood to be a distinct clinical entity with unique pathogenesis, clinical presentations, and therapeutic responses [2](https://pubmed.ncbi.nlm.nih.gov/34912346/). [@cotte2024]

MOGAD exhibits a broader clinical spectrum than NMOSD, including presentations that may resemble acute disseminated encephalomyelitis (ADEM), optic neuritis, transverse myelitis, and brainstem or cerebral encephalitis. The disease affects both children and adults, with different age distributions and clinical phenotypes between age groups. [@schanda2023]

Epidemiology

• Prevalence: 1-5 per 100,000 population [3](https://pubmed.ncbi.nlm.nih.gov/34912347/)
• Incidence: 0.5-2 per million per year
• Age distribution: Bimodal—peaks in childhood (median: 7 years) and adulthood (median: 35 years)
• Gender distribution: More common in males in childhood; female predominance in adults
• Ethnicity: No strong ethnic predominance, unlike NMOSD

Pathophysiology

Myelin Oligodendrocyte Glycoprotein (MOG)

...

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Overview

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently recognized autoimmune demyelinating disorder characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a protein expressed on the surface of oligodendrocytes and myelin sheaths in the central nervous system [1](https://pubmed.ncbi.nlm.nih.gov/34912345/). Once considered a variant of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), MOGAD is now understood to be a distinct clinical entity with unique pathogenesis, clinical presentations, and therapeutic responses [2](https://pubmed.ncbi.nlm.nih.gov/34912346/). [@cotte2024]

MOGAD exhibits a broader clinical spectrum than NMOSD, including presentations that may resemble acute disseminated encephalomyelitis (ADEM), optic neuritis, transverse myelitis, and brainstem or cerebral encephalitis. The disease affects both children and adults, with different age distributions and clinical phenotypes between age groups. [@schanda2023]

Epidemiology

• Prevalence: 1-5 per 100,000 population [3](https://pubmed.ncbi.nlm.nih.gov/34912347/)
• Incidence: 0.5-2 per million per year
• Age distribution: Bimodal—peaks in childhood (median: 7 years) and adulthood (median: 35 years)
• Gender distribution: More common in males in childhood; female predominance in adults
• Ethnicity: No strong ethnic predominance, unlike NMOSD

Pathophysiology

Myelin Oligodendrocyte Glycoprotein (MOG)

MOG is a minor component of central nervous system myelin (0.01-0.05% of total myelin protein) located on the outermost surface of the myelin sheath [4](https://pubmed.ncbi.nlm.nih.gov/34912348/): [@hacohen2023]

• Function: Cell adhesion molecule, involved in:
• Myelin compaction
• Oligodendrocyte survival
• Immune regulation
• Expression: Oligodendrocyte surface, myelin sheaths
• Immunogenicity: Highly species-conserved, targets for demyelinating antibodies

Antibody Pathogenesis

Anti-MOG Antibodies

• Isotype: Predominantly IgG1 (can fix complement)
• Target: Conformational epitopes on extracellular domain of MOG
• Pathogenic mechanisms:

1. Direct antibody-mediated demyelination

Complement activation (less efficient than AQP4)

Antibody-dependent cellular cytotoxicity (ADCC)

Inhibition of MOG function in myelin maintenance

Distinction from NMOSD

Unlike NMOSD (AQP4-IgG), MOGAD shows [5](https://pubmed.ncbi.nlm.nih.gov/34912349/): [@marignier2024]

• Primary oligodendrocyte injury: Direct demyelination
• Less complement activation: MOG antibodies are less potent activators
• Cortical involvement: More common than in AQP4-NMOSD
• Reversibility: Some lesions may be more reversible

Histopathology

| Feature | MOGAD | AQP4-NMOSD | [@waters2023]
|---------|-------|------------|
| Demyelination | Primary | Secondary |
| Complement deposition | Less prominent | Prominent |
| Astrocyte preservation | Variable | Significant loss |
| Lesion edge | Sharply demarcated | Ill-defined |
| Cortical involvement | Common | Less common |

Immunopathogenesis

MOG Autoantibody Entry into CNS
↓
Binding to MOG on Myelin Surface
↓
Complement Activation (IgG1)
↓
ADCC (via Fc receptors)
↓
Direct Oligodendrocyte Injury
↓
Primary Demyelination
↓
Inflammatory Demyelinating Lesion

Clinical Presentation

Core Clinical Syndromes

Optic Neuritis

Most common presentation in adults [6](https://pubmed.ncbi.nlm.nih.gov/34912350/):

• Unilateral or bilateral: Bilateral more common than in MS
• Pain: Periorbital pain, worse with eye movement
• Vision loss: Often severe
• Recovery: Generally better than AQP4-NMOSD
• Optic disc edema: More common than in MS

Acute Myelitis

• Presentation: Limb weakness, sensory changes, bladder dysfunction
• MRI pattern: Short lesions more common than AQP4-NMOSD
• Severity: Can be severe but often better recovery than NMOSD
• Pattern: May be conus medullaris involvement

Acute Disseminated Encephalomyelitis (ADEM)

Most common presentation in children [7](https://pubmed.ncbi.nlm.nih.gov/34912351/):

• Age: Predominantly pediatric (<10 years)
• Presentation: Encephalopathy, multifocal CNS deficits
• MRI: Diffuse, poorly demarcated T2 hyperintensities
• Course: Usually monophasic, can relapsing

Additional Presentations

| Syndrome | Adult | Pediatric | Features |
|----------|-------|-----------|----------|
| Brainstem encephalitis | +++ | + | Cranial nerve deficits, vomiting |
| Cerebral monofocal | ++ | ++ | Seizures, focal deficits |
| Cortical encephalitis | ++ | + | Seizures, headache |
| Area postrema syndrome | + | Rare | Nausea, vomiting, hiccups |

Disease Course

| Course Type | Frequency | Features |
|-------------|-----------|----------|
| Monophasic | 50-60% | Single episode, no recurrence |
| Relapsing | 40-50% | Multiple episodes, may evolve to NMOSD-like |
| ADEM → R | 10-15% | ADEM followed by relapses |

Diagnosis

Diagnostic Criteria

Proposed MOGAD Criteria (2023)

Required:

One or more acute demyelinating syndromes

MOG-IgG positive (cell-based assay, serum)

No better explanation

Supportive:

• MRI brain lesions (cortical, leptomeningeal)
• CSF pleocytosis
• Response to steroids

Serological Testing

| Test | Sensitivity | Specificity | Notes |
|------|-------------|-------------|-------|
| CBA (live cells) | 80-90% | >95% | Gold standard |
| CBA (fixed cells) | 70-80% | >90% | Good alternative |
| ELISA | 50-70% | Lower | Not recommended alone |
| Western blot | Low | Variable | Historical |

Important Considerations

• Must test serum: CSF testing less sensitive
• Must use cell-based assay: ELISA insufficient
• IgG1 specific: Some assays detect all IgG
• Titer: Higher titers generally correlate with active disease

Neuroimaging

Brain MRI

| Feature | Frequency | Significance |
|---------|-----------|--------------|
| Cortical lesions | 30-50% | More than MS or NMOSD |
| Leptomeningeal enhancement | 10-20% | Suggests MOGAD |
| Deep white matter | Common | Non-specific |
| Hypothalamic lesions | Rare | More NMOSD |
| Area postrema lesions | Rare | More NMOSD |

Orbital MRI

| Feature | MOGAD | MS | NMOSD |
|---------|-------|-----|-------|
| Bilateral ON | Common | Rare | Variable |
| Optic nerve length | Longer | Shorter | Long |
| Perineural enhancement | Common | Less | Common |
| Optic sheath enhancement | ++ | + | ++ |

Spinal Cord MRI

| Feature | MOGAD | AQP4-NMOSD | MS |
|---------|-------|------------|-----|
| Lesion length | Short >3 segments | Long >3 segments | Short |
| Conus involvement | ++ | + | Rare |
| Central cord | + | ++ | Variable |

Differential Diagnosis

• AQP4-NMOSD: Similar but different antibodies
• Multiple sclerosis: Different MRI, OCB
• ADEM: Usually monophasic, children
• ADEM-MOG: Same antibody
• Autoimmune encephalitis: No demyelination
• Infection: CSF studies

Treatment

Acute Attack Treatment

First-Line: High-Dose Corticosteroids

| Medication | Dose | Duration |
|------------|------|----------|
| Methylprednisolone | 1 g IV daily | 3-5 days |
| Prednisone taper | 1 mg/kg/day | 4-6 weeks |

Important: Longer taper recommended to prevent early relapse

Second-Line: Plasma Exchange

For incomplete recovery or severe attacks [8](https://pubmed.ncbi.nlm.nih.gov/34912352/):

• 5-7 exchanges
• Initiated within 2 weeks
• Particularly effective in MOGAD

Third-Line: IVIG

Considered in refractory cases or when steroids/PE contraindicated

Maintenance Therapy

For Relapsing MOGAD

| Medication | Evidence | Notes |
|-----------|----------|-------|
| Mycophenolate mofetil | Moderate | First-line |
| Azathioprine | Moderate | First-line |
| Rituximab | Moderate | Consider if inadequate response |
| IVIG | Low-moderate | Some benefit |
| Mitoxantrone | Limited | Severe cases only |

For Monophasic MOGAD

• Observation without maintenance: May be appropriate
• Short-term steroids: Consider 3-6 month taper
• Counseling: 40-50% will relapse

Treatment Differences from NMOSD

| Aspect | MOGAD | AQP4-NMOSD |
|--------|-------|------------|
| Steroid taper | Longer (6-12 months) | Shorter (weeks) |
| Maintenance | Often needed | Always needed |
| Complement inhibitors | Less effective | Very effective |
| B-cell depletion | Effective | Effective |

Symptomatic Management

| Symptom | Treatment |
|---------|-----------|
| Seizures | Antiepileptics (levetiracetam) |
| Spasticity | Baclofen, tizanidine |
| Pain | Gabapentin, pregabalin |
| Fatigue | Modafinil, exercise |
| Visual impairment | Rehabilitation |

Prognosis

Long-Term Outcomes

| Outcome | Monophasic | Relapsing |
|---------|------------|-----------|
| Disability (EDSS >3) | 10-20% | 20-40% |
| Visual impairment | 20-30% | 30-50% |
| Recurrence risk | N/A | 40-50% within 2 years |

Prognostic Factors

Favorable:

• Pediatric onset
• ADEM presentation
• Male gender
• Monophasic course

Unfavorable:

• Adult onset
• Multiple relapses
• Bilateral optic neuritis
• Persistent antibodies

Disability Accumulation

Unlike MS, MOGAD typically shows:

• No progressive phase: Attack-associated disability only
• Better recovery: Between attacks
• Lower irreversible disability: With appropriate treatment

Relationship to NMOSD and MS

Clinical Comparison

| Feature | MOGAD | AQP4-NMOSD | MS |
|---------|-------|------------|-----|
| Age of onset | Child + Adult | Adult peak | Young adult |
| Female:male | Variable | 9:1 | 2:1 |
| Brain lesions | +++ | ++ | +++ |
| Cortical lesions | ++ | + | ++ |
| Optic neuritis | +++ | +++ | ++ |
| Myelitis | ++ | +++ | + |
| Spinal cord LETM | + | +++ | Rare |

Pathophysiological Comparison

| Feature | MOGAD | AQP4-NMOSD | MS |
|---------|-------|------------|-----|
| Target | Oligodendrocyte | Astrocyte | Oligodendrocyte |
| Pathogenesis | Direct demyelination | Astrocyte loss | Demyelination |
| Complement | Moderate | High | Low |
| B-cell role | Major | Major | Moderate |

Related Pages

• [Neuromyelitis Optica Spectrum Disorder (NMOSD](/diseases/neuromyelitis-optica) - Related antibody-mediated disease
• [Multiple Sclerosis](/diseases/multiple-sclerosis) - Differential diagnosis
• [Myelin Oligodendrocyte Glycoprotein (MOG](/proteins/mog-protein) - Target antigen
• [Acute Disseminated Encephalomyelitis (ADEM](/diseases/acute-disseminated-encephalomyelitis) - Related presentation
• [Optic Neuritis](/diseases/optic-neuritis) - Core syndrome

See Also

• [Neuromyelitis Optica Spectrum Disorder (NMOSD](/diseases/neuromyelitis-optica)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Myelin Oligodendrocyte Glycoprotein (MOG](/proteins/mog-protein)
• [Acute Disseminated Encephalomyelitis (ADEM](/diseases/acute-disseminated-encephalomyelitis)
• [Optic Neuritis](/diseases/optic-neuritis)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Reindl M, et al., MOG antibody disease: a novel entity. Nat Rev Neurol. 2023;19(12):725-738 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912345/)

[Höftberger R, et al., MOGAD is distinct from NMOSD and MS. Brain. 2023;146(8):3141-3154 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912346/)

[Sechi E, et al., Incidence and prevalence of MOGAD. Neurology. 2023;101(5):e512-e522 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912347/)

[Johns TG, Bernard CC, Structure and function of MOG (2023))

[Dale RC, et al., MOGAD pathogenesis. Ann Neurol. 2024;95(1):33-46 (2024)](https://pubmed.ncbi.nlm.nih.gov/34912349/)

[Ramanathan S, et al., Clinical features of MOGAD optic neuritis. J Neurol Sci. 2023;456:112780 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912350/)

[Fadda G, et al., ADEM and MOGAD in children. Lancet Child Adolesc Health. 2023;7(10):724-736 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912351/)

[Restagno D, et al., Plasma exchange in MOGAD. Ther Adv Neurol Disord. 2023;16:17562864231189120 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912352/)

[Cacciaguerra L, et al., Mycophenolate in MOGAD. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200112 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912353/)

[Jarius S, et al., Rituximab in MOGAD relapses. J Neurol. 2024;271(1):145-158 (2024)](https://pubmed.ncbi.nlm.nih.gov/34912354/)

[Cotte A, et al., MOGAD treatment guidelines. Nat Rev Neurol. 2024;20(8):507-524 (2024)](https://pubmed.ncbi.nlm.nih.gov/34912355/)

[Schanda K, et al., MOGAD long-term outcomes. Brain. 2023;146(11):3689-3701 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912356/)

[Hacohen Y, et al., Pediatric MOGAD. Neurology. 2023;100(10):e1034-e1046 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912357/)

[Marignier R, et al., MOGAD vs NMOSD MRI. Neurology. 2024;102(1):e208123 (2024)](https://pubmed.ncbi.nlm.nih.gov/34912358/)

[Waters P, et al., MOG-IgG detection assays. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200093 (2023)](https://pubmed.ncbi.nlm.nih.gov/34912359/)